Cargando…
Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy
BACKGROUND: Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long‐term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome i...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751885/ https://www.ncbi.nlm.nih.gov/pubmed/34634920 http://dx.doi.org/10.1161/JAHA.120.021936 |
_version_ | 1784631772958425088 |
---|---|
author | Tesic, Milorad Beleslin, Branko Giga, Vojislav Jovanovic, Ivana Marinkovic, Jelena Trifunovic, Danijela Petrovic, Olga Dobric, Milan Aleksandric, Srdjan Juricic, Stefan Boskovic, Nikola Tomasevic, Miloje Ristic, Arsen Orlic, Dejan Stojkovic, Sinisa Vukcevic, Vladan Stankovic, Goran Ostojic, Miodrag Djordjevic Dikic, Ana |
author_facet | Tesic, Milorad Beleslin, Branko Giga, Vojislav Jovanovic, Ivana Marinkovic, Jelena Trifunovic, Danijela Petrovic, Olga Dobric, Milan Aleksandric, Srdjan Juricic, Stefan Boskovic, Nikola Tomasevic, Miloje Ristic, Arsen Orlic, Dejan Stojkovic, Sinisa Vukcevic, Vladan Stankovic, Goran Ostojic, Miodrag Djordjevic Dikic, Ana |
author_sort | Tesic, Milorad |
collection | PubMed |
description | BACKGROUND: Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long‐term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long‐term prognostic value of CFVR on clinical outcome in HCM population. METHODS AND RESULTS: We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients’ clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requiring hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depending on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow‐up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P<0.001 vs. Group 1) adverse cardiac events. By Kaplan‐Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event‐free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log‐rank 37.2, P<0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83–16.30, P<0.001), while CFVR PD was not significantly associated with outcome. CONCLUSIONS: In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant. |
format | Online Article Text |
id | pubmed-8751885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87518852022-01-14 Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy Tesic, Milorad Beleslin, Branko Giga, Vojislav Jovanovic, Ivana Marinkovic, Jelena Trifunovic, Danijela Petrovic, Olga Dobric, Milan Aleksandric, Srdjan Juricic, Stefan Boskovic, Nikola Tomasevic, Miloje Ristic, Arsen Orlic, Dejan Stojkovic, Sinisa Vukcevic, Vladan Stankovic, Goran Ostojic, Miodrag Djordjevic Dikic, Ana J Am Heart Assoc Original Research BACKGROUND: Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long‐term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long‐term prognostic value of CFVR on clinical outcome in HCM population. METHODS AND RESULTS: We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients’ clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requiring hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depending on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow‐up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P<0.001 vs. Group 1) adverse cardiac events. By Kaplan‐Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event‐free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log‐rank 37.2, P<0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83–16.30, P<0.001), while CFVR PD was not significantly associated with outcome. CONCLUSIONS: In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant. John Wiley and Sons Inc. 2021-10-12 /pmc/articles/PMC8751885/ /pubmed/34634920 http://dx.doi.org/10.1161/JAHA.120.021936 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Tesic, Milorad Beleslin, Branko Giga, Vojislav Jovanovic, Ivana Marinkovic, Jelena Trifunovic, Danijela Petrovic, Olga Dobric, Milan Aleksandric, Srdjan Juricic, Stefan Boskovic, Nikola Tomasevic, Miloje Ristic, Arsen Orlic, Dejan Stojkovic, Sinisa Vukcevic, Vladan Stankovic, Goran Ostojic, Miodrag Djordjevic Dikic, Ana Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title | Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title_full | Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title_fullStr | Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title_full_unstemmed | Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title_short | Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy |
title_sort | prognostic value of transthoracic doppler echocardiography coronary flow velocity reserve in patients with asymmetric hypertrophic cardiomyopathy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751885/ https://www.ncbi.nlm.nih.gov/pubmed/34634920 http://dx.doi.org/10.1161/JAHA.120.021936 |
work_keys_str_mv | AT tesicmilorad prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT beleslinbranko prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT gigavojislav prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT jovanovicivana prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT marinkovicjelena prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT trifunovicdanijela prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT petrovicolga prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT dobricmilan prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT aleksandricsrdjan prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT juricicstefan prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT boskovicnikola prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT tomasevicmiloje prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT risticarsen prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT orlicdejan prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT stojkovicsinisa prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT vukcevicvladan prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT stankovicgoran prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT ostojicmiodrag prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy AT djordjevicdikicana prognosticvalueoftransthoracicdopplerechocardiographycoronaryflowvelocityreserveinpatientswithasymmetrichypertrophiccardiomyopathy |